
Forte Biosciences (FBRX) Stock Forecast & Price Target
Forte Biosciences (FBRX) Analyst Ratings
Bulls say
Forte Biosciences Inc. is advancing its product candidate, FB-102, which has the potential to target multiple autoimmune disorders, capitalizing on the untapped market opportunities within these indications. The significant increase in research and development expenses, rising from $5.9 million to $15.2 million year-over-year, reflects the company's commitment to progressing its therapeutic pipeline through clinical trials. With growing market interest evident from competitors' successes and emerging therapies in the space, FB-102 may emerge as a preferred first-line treatment option, enhancing its market share and financial performance prospects.
Bears say
Forte Biosciences faces significant challenges due to intense market competition from both existing and emerging therapies, which could impede its ability to penetrate the market and affect pricing strategies. Additionally, potential delays in clinical development, regulatory approvals, or commercialization timelines may extend development periods and inflate costs, further straining financial performance. The company also exhibits technical difficulties in its development processes, including failures in NK cell development and impaired Treg homeostasis, which raises concerns about the viability of its product candidate, FB-102.
This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Forte Biosciences (FBRX) Analyst Forecast & Price Prediction
Start investing in Forte Biosciences (FBRX)
Order type
Buy in
Order amount
Est. shares
0 shares